FrancophonIA/ELRC3.0 huggingface dataset:
English: darunavir/cobicistat (anti-HIV medicine) - carbamazepine, phenobarbital, phenytoin (medicines to prevent seizures) - rifampicin, because it is contraindicated with boosted protease inhibitors, and rifapentine
Slovenian: darunavir/kobicistat (zdravila proti HIV) - karbamazepin, fenobarbital, fenitoin (zdravila za preprečevanje epileptičnih napadov) - rifampicin, ker je njegova uporaba skupaj z okrepljenimi zaviralci proteaz kontraindicirana in rifapentin (učinkovini za zdravljenje nekaterih okužb, na primer tuberkuloze) - izdelki, ki vsebujejo šentjanževko (Hypericum perforatum) (zeliščni pripravek proti depresiji) - daklatasvir, simeprevir (zdravili za zdravljenje okužbe z virusom hepatitisa C)
English: Co-administration of etravirine with atazanavir/cobicistat or darunavir/cobicistat may decrease plasma concentrations of the PI and/or cobicistat, which may result in loss of therapeutic effect and development of resistance.
Slovenian: Sočasna uporaba etravirina s kombinacijo atazanavir/kobicistat ali darunavir/kobicistat lahko zmanjša plazemske koncentracije PI in/ali kobicistata, kar lahko povzroči izgubo terapevtskega učinka in razvoj odpornosti.
English: n = 9 for AUC12h
Slovenian: AUC12h, h*ng /ml n = 9 za AUC12h
English: There was no gender difference in severity or treatment discontinuation due to rash.
Slovenian: Pri izrazitosti izpuščaja ali ukinitvi zdravila zaradi izpuščaja, med spoloma ni bilo razlik.
English: Medicinal products that induce CYP3A4, CYP2C9 or CYP2C19 may increase the clearance of etravirine, resulting in lowered plasma concentrations of etravirine.
Slovenian: Zdravila, ki inducirajo izoencime CYP3A4, CYP2C9 ali CYP2C19, lahko povečajo očistek etravirina in povzročijo zmanjšanje plazemske koncentracije etravirina.
English: Rifampicin and rifapentine are expected to decrease plasma concentrations of etravirine.
Slovenian: Pričakovati je, da rifampicin in rifapentin znižata plazemsko koncentracijo etravirina.
English: No interaction study has been performed.
Slovenian: Medsebojnih delovanj niso preučevali.
English: Darunavir/ritonavir 600/100 mg twice daily darunavir
Slovenian: darunavir/ritonavir 600/100 mg dvakrat na dan darunavir
English: TMC125-C213 12 to < 18 years ETR N = 60
Slovenian: TMC125-C213 12 do < 18 let ETR N = 60
English: Etravirine significantly reduced plasma concentrations of dolutegravir.
Slovenian: Etravirin pomembno zniža plazemske koncentracije dolutegravirja.
English: There was no teratogenicity with etravirine in rats and rabbits at exposures equivalent to those observed in humans at the recommended clinical dose.
Slovenian: Etravirin ni bil teratogen za podgane in kunce pri enakih stopnjah izpostavljenosti, kot so jih ugotovili pri človeku ob uporabi priporočenega kliničnega odmerka.
English: Haemorrhagic cardiomyopathy was only observed in male mice and was considered to be secondary to severe coagulopathy mediated via the vitamin K pathway.
Slovenian: Hemoragično kardiomiopatijo so opazili samo pri mišjih samcih in so jo šteli za sekundarno, saj nastane kot posledica hude koagulopatije zaradi motnje v poti vitamina K. Pri podganah so bili bistveni ugotovljeni tarčni organi jetra, žleza ščitnica in sistem strjevanja krvi.
English: Cmax ↓ 0.55 (0.40-0.75) N-desmethyl-sildenafil AUC ↓ 0.59 (0.52-0.68) Cmin ND
Slovenian: Cmax ↓ 0,55 (0,40-0,75) N-demetil-sildenafil AUC ↓ 0,59 (0,52-0,68) Cmin ND
English: AUC ↑ 3.10 (2.57-3.74) Cmin ↑ 5.27 (4.51-6.15) Cmax ↑ 1.77 (1.20-2.60) * compared to maraviroc 150 mg twice daily
Slovenian: AUC ↑ 3,10 (2,57-3,74) Cmin ↑ 5,27 (4,51-6,15) Cmax ↑ 1,77 (1,20-2,60) *v primerjavi z odmerkom maraviroka 150 mg dvakrat na dan
English: Population pharmacokinetic analysis of the DUET-1 and DUET-2 trials showed reduced clearance (potentially leading to increased exposure and alteration of the safety profile) for etravirine in HIV-1 infected patients with hepatitis B and/or hepatitis C virus co-infection.
Slovenian: Sočasna okužba z virusom hepatitisa B in/ali hepatitisa C Analiza populacijske farmakokinetike iz preskušanj DUET-1 in DUET-2 je pokazala zmanjšan očistek (kar lahko vodi v povečano izpostavljenost in spremembo varnostnega profila) etravirina pri bolnikih, okuženih s HIV-1, ki so bili sočasno okuženi z virusom hepatitisa B in/ali z virusom hepatitisa C. Glede na to, da so na voljo le omejeni podatki o bolnikih, ki so sočasno okuženi z virusom hepatitisa B in/ali C, je pri uporabi zdravila INTELENCE pri teh bolnikih potrebna posebna previdnost (glejte poglavji 4.4 in 4.8).
English: 8 weeks after opening the bottle.
Slovenian: 2 leti 8 tednov po prvem odpiranju plastenke.
English: In the dog, changes were observed in the liver and gall bladder at exposures approximately 8-fold higher than human exposure observed at the recommended dose (200 mg twice daily).
Slovenian: Pri psih so med jemanjem priporočenega odmerka (200 mg dvakrat na dan) opažali spremembe v jetrih in žolčniku pri stopnjah izpostavljenosti, ki so bile približno 8-krat večje od stopnje izpostavljenosti pri človeku.
English: - The other ingredients are hypromellose, silicified microcrystalline cellulose, microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium and magnesium stearate.
Slovenian: - Druge sestavine zdravila so hipromeloza, mikrokristalna celuloza, silicirana mikrokristalna celuloza, koloidni brezvodni silicijev dioksid, premreženi natrijev karmelozat in magnezijev stearat.
English: Maraviroc/darunavir/ ritonavir
Slovenian: fosamprenavir/ritonavi
English: EXP Do not use after 6 weeks of first opening the bottle.
Slovenian: EXP Zdravila ne uporabljajte več kot 6 tednov po prvem odpiranju plastenke.
English: Janssen-Cilag AB Tfn: +46 8 626 50 00 jacse@its.jnj.com
Slovenian: Janssen-Cilag AB Tel: +46 8 626 50 00 jacse@its.jnj.com
English: Furthermore, the presence of this mutation alone did not affect the response in the etravirine arm. Additional data is required to conclude on the influence of K103N when associated with other NNRTIs mutations.
Slovenian: Za oceno vpliva K103N skupaj z drugimi mutacijami NNRTI so potrebni dodatni podatki.
English: The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease.
Slovenian: Med dejavnike tveganja za pojav te bolezni spadajo tudi trajanje kombiniranega protiretrovirusnega zdravljenja, uporaba kortikosteroidov, uživanje alkohola, huda imunosupresija in višji indeks telesne mase.
English: Baseline genotype or phenotype and virologic outcome analyses In DUET-1 and DUET-2, the presence at baseline of 3 or more of the following mutations: V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A and G190S, (etravirine RAMs) was associated with a decreased virologic response to etravirine (see table 5).
Slovenian: Začetni genotip ali fenotip in analize virološkega izida V študijah DUET-1 in DUET-2 je bila navzočnost 3 ali več mutacij izmed V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A ali G190S (RAM etravirina) na začetku študije povezana z zmanjšanim virološkim odzivom na etravirin (glejte preglednico 5).
English: Placebo arms N = 569
Slovenian: Kraki študije za placebo N = 569
English: Concomitant use of etravirine with efavirenz or nevirapine may cause a significant decrease in the plasma concentration of etravirine and loss of therapeutic effect of etravirine.
Slovenian: Sočasna uporaba etravirina in efavirenza ali nevirapina lahko povzroči pomembno zmanjšnje plazemske koncentracije etravirina in izgubo terapevtskega učinka etravirina.
English: TMC125-C213 6 to < 18 years ETR N = 101
Slovenian: TMC125-C213 6 do < 18 let ETR N = 101
English: Sensitivity of the virus to etravirine at screening was required.
Slovenian: Ob začetku študije je bilo potrebno dokazati občutljivost na etravirin.
English: If you notice after 6 hours, then skip the intake and take the next doses as usual.
Slovenian: Če pa se na zdravilo spomnite šele po 6 urah, preskočite pozabljeni odmerek in vzemite naslednje odmerke kot običajno.
English: Follow your doctor's instruction carefully on which medicines can be combined.
Slovenian: Natančno morate tudi upoštevati zdravnikova navodila o tem, katera zdravila smete jemati sočasno z zdravilom INTELENCE.
English: In other cases, increased monitoring and/or a change in the dose of the medicine may be needed.
Slovenian: V drugih primerih je potreben zvečan nadzor in/ali sprememba odmerka zdravila, zato morate zdravniku vedno povedati za vsa druga zdravila proti HIV, ki jih jemljete.
English: 6 weeks after opening the bottle.
Slovenian: 2 leti 6 tednov po prvem odpiranju plastenke.
English: Patients should be informed to seek medical advice if severe rash or hypersensitivity reactions occur.
Slovenian: Bolnike je treba poučiti, da morajo v primeru pojava hudega izpuščaja ali preobčutljivostne reakcije poiskati zdravniško pomoč.
English: Do not stop taking INTELENCE without talking to your doctor first HIV therapy may increase your sense of well-being.
Slovenian: Ne prenehajte z jemanjem zdravila INTELENCE, ne da bi se najprej posvetovali s svojim zdravnikom
English: 6 cells/l), mean (SE) and median (range) Change from baseline in CD4 percentage, median (range)
Slovenian: 6 celic/l) glede na začetek, povprečje (SE) in mediana (razpon)
English: EXP Do not use after 8 weeks of first opening the bottle.
Slovenian: EXP Zdravila ne uporabljajte več kot 8 tednov po prvem odpiranju plastenke.
English: Table 2: Adverse reactions observed with etravirine in clinical trials and post-marketing experience
Slovenian: Preglednica 2: Neželeni učinki, ki so jih opažali pri uporabi etravirina v kliničnih preskušanjih in po prihodu zdravila na trg Razvrstitev po organskih sistemih (SOC)
English: General disorders and administration site conditions common fatigue uncommon sluggishness
Slovenian: Splošne težave in spremembe na mestu aplikacije pogosti utrujenost občasni upočasnjenost
English: Etravirine arms N = 549
Slovenian: Kraki študije za etravirin N = 549
English: Etravirine is an NNRTI of human immunodeficiency virus type 1 (HIV-1).
Slovenian: Etravirin je nenukleozidni zaviralec virusnega (HIV-1) encima reverzna transkriptaza.
English: Recommended dose of etravirine for paediatric patients 6 years to less than 18 years of age Body weight
Slovenian: Priporočeni odmerek etravirina pri pediatričnih bolnikih (od 6 let do manj kot 18 let) telesna masa odmerek tablete
English: If you vomit more than 4 hours after taking INTELENCE, then you do not need to take another dose until your regularly scheduled dose.
Slovenian: Če bruhate po več kot 4 urah od takrat, ko ste vzeli zdravilo INTELENCE, vam ni treba vzeti dodatnega odmerka, dokler ni čas za naslednji redni odmerek.
English: 40 mg once daily etravirine
Slovenian: 40 mg enkrat na dan etravirin
English: Dolutegravir + Lopinavir/ritonavir 50 mg once daily + 400/100 mg twice daily dolutegravir AUC ↓ 0.29 (0.26-0.34) Cmin ↓ 0.12 (0.09-0.16) Cmax ↓ 0.48 (0.43-0.54) etravirine
Slovenian: 50 mg enkrat na dan dolutegravir + darunavir/ritonavir 50 mg enkrat na dan + 600/100 mg dvakrat na dan dolutegravir + lopinavir/ritonavir 50 mg enkrat na dan + 400/100 mg dvakrat na dan dolutegravir AUC ↓ 0,29 (0,26-0,34) Cmin ↓ 0,12 (0,09-0,16) Cmax ↓ 0,48 (0,43-0,54) etravirin
English: INTELENCE contains lactose
Slovenian: Zdravilo INTELENCE vsebuje laktozo
English: INTELENCE contains the active substance etravirine.
Slovenian: Zdravilo INTELENCE vsebuje učinkovino etravirin.
English: Lovastatin, rosuvastatin and simvastatin are CYP3A4 substrates and co-administration with etravirine may result in lower plasma concentrations of the HMG Co-A reductase inhibitor.
Slovenian: Lovastatin, rosuvastatin in simvastatin so substrati za CYP3A4 in njihova sočasna uporaba z etravirinom lahko povzroči manjše plazemske koncentracije zaviralca HMG Co-A reduktaze.
English: Excipient with known effect Each tablet contains less than 1 mmol sodium (23 mg), and is essentially sodium-free.
Slovenian: Pomožna snov z znanim učinkom Ena tableta vsebuje manj kot 1 mmol (23 mg) natrija, kar v bistvu pomeni ‘brez natrija'.
English: Co-administration of INTELENCE with atazanavir/cobicistat or darunavir/cobicistat is not recommended.
Slovenian: Sočasna uporaba zdravila INTELENCE s kombinacijo atazanavir/kobicistat ali darunavir/kobicistat ni priporočljiva.
English: It is not recommended to co-administer INTELENCE with nelfinavir.
Slovenian: Sočasna uporaba zdravila INTELENCE z nelfinavirjem ni priporočljiva.
English: Amprenavir/ritonavir and fosamprenavir/ritonavir may require dose reduction when co-administered with INTELENCE.
Slovenian: Lahko je potrebna prilagoditev odmerka kombinacije amprenavir/ritonavir in fosamprenavir/ritonavir pri sočasni uporabi z zdravilom INTELENCE.
English: This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium free'.
Slovenian: Ena tableta vsebuje manj kot 1 mmol (23 mg) natrija, kar v bistvu pomeni ‘brez natrija'.
English: Clarithromycin 500 mg twice daily clarithromycin AUC ↓ 0.61 (0.53-0.69) Cmin ↓ 0.47 (0.38-0.57) Cmax ↓ 0.66 (0.57-0.77) 14-OH-clarithromycin AUC ↑ 1.21 (1.05-1.39) Cmin ↔ 1.05 (0.90-1.22) Cmax ↑ 1.33 (1.13-1.56) etravirine
Slovenian: klaritromicin 500 mg dvakrat na dan klaritromicin AUC ↓ 0,61 (0,53-0,69) Cmin ↓ 0,47 (0,38-0,57) Cmax ↓ 0,66 (0,57-0,77) 14-OH-klaritromicin AUC ↑ 1,21 (1,05-1,39) Cmin ↔ 1,05 (0,90-1,22) Cmax ↑ 1,33 (1,13-1,56) etravirin
English: Confirmed undetectable viral load (< 50 HIV-1 RNA copies/ml) n (%)
Slovenian: Izid zdravljenja Potrjeno nemerljivo virusno breme (< 50 HIV-1 RNK kopij/ml) n (%) celokupno de novo ENF
English: Simultaneously, plasma concentrations of itraconazole or ketoconazole may be decreased by etravirine.
Slovenian: Hkrati pa lahko etravirin zniža plazemske koncentracije itrakonazola ali ketokonazola.
English: The presence of K103N alone, which was the most prevalent NNRTI mutation in DUET-1 and DUET-2 at baseline, was not identified as a mutation associated with resistance to etravirine.
Slovenian: Prisotnost samo K103N ni bila opredeljena kot mutacija, povezana z odpornostjo na etravirin.
English: C-etravirine dose, 93.7% and 1.2% of the administered dose of C-etravirine could be retrieved in faeces and urine, respectively.
Slovenian: so v blatu našli 93,7% prejetega odmerka etravirina-C
English: ANTI-INFECTIVES Antiretrovirals NRTIs
Slovenian: ZDRAVILA ZA ZDRAVLJENJE INFEKCIJ Protiretrovirusna zdravila NRTI (nukleozidni zaviralci reverzne transkriptaze)
English: Treatment-experienced paediatric patients (6 years to less than 18 years of age) PIANO is a single-arm, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of etravirine in 101 antiretroviral treatment-experienced HIV-1 infected paediatric patients 6 years to less than 18 years of age and weighing at least 16 kg.
Slovenian: faze z eno skupino bolnikov v katerem so ocenjevali farmakokinetiko, varnost, prenosljivost in učinkovitost etravirina pri 101 s HIV-1 okuženem pediatričnem bolniku, ki se je že zdravil s protiretrovirusnimi zdravili, starem 6 let do manj kot 18 let in s telesno maso najmanj 16 kg.
English: R(-) methadone AUC ↔ 1.06 (0.99-1.13) Cmin ↔ 1.10 (1.02-1.19) Cmax ↔ 1.02 (0.96-1.09) S(+) methadone AUC ↔ 0.89 (0.82-0.96) Cmin ↔ 0.89 (0.81-0.98) Cmax ↔ 0.89 (0.83-0.97) etravirine
Slovenian: R(-) metadon AUC ↔ 1,06 (0,99-1,13) Cmin ↔ 1,10 (1,02-1,19) Cmax ↔ 1,02 (0,96-1,09) S(+) metadon AUC ↔ 0,89 (0,82-0,96) Cmin ↔ 0,89 (0,81-0,98) Cmax ↔ 0,89 (0,83-0,97) etravirin
English: Concomitant use of etravirine with indinavir may cause a significant decrease in the plasma concentration of indinavir and loss of therapeutic effect of indinavir.
Slovenian: Sočasna uporaba etravirina in indinavirja lahko povzroči pomembno znižanje plazemske koncentracije indinavirja in izgubo njegovega terapevtskega učinka.
English: Do not use after 8 weeks of first opening the bottle.
Slovenian: Zdravila ne uporabljajte več kot 8 tednov po prvem odpiranju plastenke.
English: Co-administration of etravirine with elbasvir/grazoprevir may decrease elbasvir and grazoprevir concentrations, leading to reduced therapeutic effect of elbasvir/grazoprevir.
Slovenian: Sočasna uporaba etravirina in kombinacije elbasvir/grazoprevir lahko zmanjša koncentracije elbasvirja in grazoprevirja ter zmanjša terapevtski učinek kombinacije.
English: Co-administration of etravirine and medicinal products that inhibit CYP3A4, CYP2C9 or CYP2C19 may decrease the clearance of etravirine and may result in increased plasma concentrations of etravirine.
Slovenian: Sočasna uporaba etravirina in zdravil, ki zavirajo CYP3A4, CYP2C9 ali CYP2C19, pa lahko zmanjša očistek etravirina in tako povzroči zvečanje plazemske koncentracije etravirina.
English: Concomitant use of etravirine with rilpivirine may cause a decrease in the plasma concentration of rilpivirine and loss of therapeutic effect of rilpivirine.
Slovenian: Sočasna uporaba etravirina in rilpivirina lahko povzroči znižanje plazemske koncentracije rilpivirina in izgubo njegovega terapevtskega učinka.
English: Do not use after 6 weeks of first opening the bottle.
Slovenian: Zdravila ne uporabljajte več kot 6 tednov po prvem odpiranju plastenke.
English: Co-administration of Intelence and simeprevir is not recommended.
Slovenian: Sočasna uporaba zdravila INTELENCE in simeprevirja ni priporočljiva.
English: INTELENCE and tenofovir can be used without dose adjustments.
Slovenian: INTELENCE in tenofovir se lahko uporabljata brez prilagajanja odmerkov.
English: Non-completer is failure (NC = F) imputation.
Slovenian: Bolnik, ki ne dokonča preskušanja, se mu pripiše vrednost: neuspešno zdravljenje (NC = F)
English: HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS Ribavirin
Slovenian: PROTIVIRUSNA ZDRAVILA Z NEPOSREDNIM DELOVANJEM NA VIRUS HEPATITISA C (HCV)
English: Very common side effects (may affect more than 1 in 10 people) - skin rash.
Slovenian: Zelo pogosti neželeni učinki (pojavijo se pri več kot 1 od 10 bolnikov) - kožni izpuščaj, ki je običajno blag do zmeren.
English: PLATELET AGGREGGATION INHIBITORS Clopidogrel
Slovenian: ZAVIRALCI AGREGACIJE TROMBOCITOV klopidogrel
English: Uncommon side effects (may affect up to 1 in 100 people) - decreased number of white blood cells; - symptoms of infection (for example enlarged lymph nodes and fever); - abnormal dreams, confusion, disorientation, nervousness, nightmares; - drowsiness, trembling, fainting, seizures, disturbance in attention; - dizziness, sluggishness; - angina, irregular heart rhythm; - difficulty breathing; - retching, inflammation of the pancreas, vomiting blood; - liver problems such as hepatitis, enlarged liver; - excessive sweating, swelling of the face and/or throat; - swelling of breasts in men.
Slovenian: Občasni neželeni učinki (pojavijo se pri največ 1 od 100 bolnikov) - zmanjšano število levkocitov - simptomi okužbe (na primer povečane bezgavke ali zvišana telesna temperatura) - nenormalne sanje, zmedenost, dezorientacija, živčnost, nočne more - dremavost, tresenje, omedlevica, epileptični napadi, motnje pozornosti - omotica, upočasnjenost - angina pektoris, motnje srčnega ritma - težave z dihanjem - siljenje na bruhanje, vnetje trebušne slinavke, bruhanje krvi - jetrne bolezni, npr. hepatitis, povečana jetra - prekomerno potenje, otekanje obraza in/ali žrela - zvečanje prsi pri moških.
English: Fluvastatin, and rosuvastatin are metabolised by CYP2C9 and co-administration with etravirine may result in higher plasma concentrations of the HMG Co-A reductase inhibitor.
Slovenian: Fluvastatin in rosuvastatin se presnavljata s CYP2C9 in njuna sočasna uporaba z etravirinom lahko vodi do večjih plazemskih koncentracij zaviralca HMG Co-A reduktaze.
English: INTELENCE can be used with these NRTIs without dose adjustment.
Slovenian: INTELENCE se skupaj s temi NRTI lahko uporablja brez prilagajanja odmerkov.
English: How to store INTELENCE
Slovenian: Shranjevanje zdravila INTELENCE
English: Rash was mostly self-limiting and generally resolved within 1 week on continued therapy.
Slovenian: Večinoma je bil omejen in je ob nadaljevanju zdravljenja izginil v enem tednu.
English: Boosted protease inhibitors, like darunavir/ritonavir, show a higher barrier to resistance compared to other classes of antiretrovirals.
Slovenian: darunavir/ritonavir), višjo mejo za razvoj odpornosti.
English: Rash was most frequently mild to moderate, generally macular to maculopapular or erythematous, mostly occurred in the second week of therapy, and was infrequent after week 4.
Slovenian: Izpuščaj je bil najpogosteje blag do zmeren, običajno je bil makularen do makulopapularen ali eritematozen.
English: The effect of etravirine on dolutegravir plasma concentrations was mitigated by co-administration of darunavir/ritonavir or lopinavir/ritonavir, and is expected to be mitigated by atazanavir/ritonavir.
Slovenian: Učinek etravirina na koncentracijo dolutegravirja v plazmi je ublažila sočasna kombinacija darunavir/ritonavir ali lopinavir/ritonavir.
English: The patient should be instructed to do the following: - place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medicine, - stir well until the water looks milky, - if desired, add more water or alternatively orange juice or milk (patients should not place the tablets in orange juice or milk without first adding water), - drink it immediately, - rinse the glass several times with water, orange juice, or milk and completely swallow the rinse each time to make sure the patient takes the entire dose.
Slovenian: (e) z vodo, - dobro premeša tako, da voda izgleda kot mleko, - po želji doda vodo, pomarančni sok ali mleko (tablet ne sme dati neposredno v pomarančni sok ali mleko), - takoj popije, - kozarec večkrat spere z vodo, pomarančnim sokom ali mlekom in vsakič popije tudi vso tekočino, s katero je spral kozarec, da bo prejel celotni odmerek.
English: Gastrointestinal very common diarrhoea, nausea disorders common gastrooesophageal reflux disease, vomiting, abdominal pain, abdominal distension, flatulence, gastritis, constipation, dry mouth, stomatitis, lipase increased, blood amylase increased uncommon pancreatitis, haematemesis, retching Hepatobiliary disorders common increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST) uncommon hepatitis, hepatic steatosis, cytolytic hepatitis, hepatomegaly
Slovenian: Bolezni prebavil zelo pogosti driska, navzea pogosti gastroezofagealni refluks, bruhanje, trebušne bolečine, napihnjenost trebuha, napenjanje, gastritis, zaprtje, suha usta, stomatitis, zvečanje koncentracije lipaze, zvečanje koncentracije amilaze v krvi občasni pankreatitis, hematemeza, siljenje na bruhanje
English: This combination can be used without dose adjustment.
Slovenian: Pri teh kombinacijah prilagoditev odmerka ni potrebna.
English: nd trimester of pregnancy as compared to postpartum, and 1.1-, 1.4- and 1.2-fold higher, respectively, based during the 3
Slovenian: Primerjava med posameznimi bolnicami je pokazala, da so bile vrednosti Cmin, Cmax in AUC12h za 1,2-; 1,4- oziroma 1,4-krat večje med drugim trimesečjem nosečnosti in za 1,1-; 1,4- oziroma 1,2-krat večje med tretjim trimesečjem nosečnosti v primerjavi z obdobjem po porodu.
English: Each tablet contains 160 mg of lactose monohydrate.
Slovenian: Ena tableta vsebuje 160 mg laktoze monohidrata.
English: If a patient misses a dose by more than 6 hours of the time it is usually taken, the patient should not take the missed dose and simply resume the usual dosing schedule.
Slovenian: Če zamudi jemanje odmerka za več kot 6 ur od običajnega časa, naj preskoči zamujeni odmerek in preprosto nadaljuje z običajnim jemanjem zdravila.
English: Each tablet contains 40 mg of lactose monohydrate.
Slovenian: Ena tableta vsebuje 40 mg laktoze monohidrata.
English: Daclatasvir
Slovenian: daklatasvir
English: Etravirine was not carcinogenic in rats and in male mice.
Slovenian: V preskušanjih na podganah in samcih miši etravirin ni bil kancerogen.
English: ANTIMYCOBACTERIALS Rifampicin
Slovenian: UČINKOVINE ZA ZDRAVLJENJE INFEKCIJ Z MIKOBAKTERIJAMI rifampicin rifapentin